Art. -Nr.: HY-100198

Copy Link Print Information

PI4KIIIbeta-IN-10

15 Cited Publications

Kundenbewertung

Based on 15 publication(s) in Google Scholar

PI4KIIIbeta-IN-10 is a potent PI4KIIIβ inhibitor with an IC₅₀ of 3.6 nM.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.84%
CAS. Nr.: 1881233-39-1
Formel: C₂₂H₂₅N₃O₅S₂
Molecular Weight:475.58

Speicherung:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

PI4KIIIbeta-IN-10 Chemical Structure

CAS. Nr.: 1881233-39-1

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- Cellular Effect
- In Vitro
Chemical Information
Publications (15)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Protokoll
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

PI4KIIIbeta-IN-10 is a potent PI4KIIIβ inhibitor with an IC₅₀ of 3.6 nM.

IC₅₀ & Target^[1]

PI4KIIIβ

3.6 nM (IC₅₀)

PI4KIIIα

3 μM (IC₅₀)

PI3Kδ

720 nM (IC₅₀)

PI3KC2γ

1 μM (IC₅₀)

PI3Kα

10 μM (IC₅₀)

PI3Kγ

20 μM (IC₅₀)

Alle PI4K Isoform-spezifische Produkte anzeigen :

Alle PI3K Isoform-spezifische Produkte anzeigen :

Cellular Effect

Cell Line	Type	Value	Description	References
Huh-7	IC₅₀	1300 nM Compound: 10	Antiviral activity against HCV genotype 2a J6/JFH1 infected in human Huh7.5 cells after 3 days by gaussia luciferase assay Antiviral activity against HCV genotype 2a J6/JFH1 infected in human Huh7.5 cells after 3 days by gaussia luciferase assay	[PMID: 26885694]
Huh-7	CC₅₀	32 μM Compound: 10	Cytotoxicity against human Huh7.5 cells after 3 days by presto blue assay Cytotoxicity against human Huh7.5 cells after 3 days by presto blue assay	[PMID: 26885694]

In Vitro

PI4KIIIbeta-IN-10 (Compound 10) is a potent PI4KIIIβ inhibitor with very minor off-target inhibition of PI4KIIIβ related lipid kinases. PI4KIIIbeta-IN-10 shows weak inhibition of PI3KC2γ (IC₅₀ ~1 μM), PI3Kα (~10 μM), and PI4KIIIα (~3 μM), and <20% inhibition at concentrations up to 20 μM for PI4K2α, PI4K2β, and PI3Kβ^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Chemical Information

CAS. Nr. 1881233-39-1
Appearance Solid
Molecular Weight 475.58
Formel C₂₂H₂₅N₃O₅S₂
Color White to off-white
SMILES

COC1=CC=C(C2=C(C)N=C(NC(C(C)(C)C)=O)S2)C=C1S(NC3=CC=C(O)C=C3)(=O)=O
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (15)

All Cell Proliferation/Viability AssayWB

Sort by:

Journal Impact Factor

Nat Immunol

Distinct changes in endosomal composition promote NLRP3 inflammasome activation. [Abstract]

2023 Jan;24(1):30-41. PMID: 36443515
J Extracell Vesicles

Function of ceramide transfer protein for biogenesis and sphingolipid composition of extracellular vesicles. [Abstract]

2022 Jun;11(6):e12233. PMID: 35642450
Autophagy

VAMP associated proteins are required for autophagic and lysosomal degradation by promoting a PtdIns4P-mediated endosomal pathway. [Abstract]

2019 Jul;15(7):1214-1233. PMID: 30741620

PI4KIIIbeta-IN-10 purchased from MedChemExpress. Usage Cited in: Autophagy. 2019 Jul;15(7):1214-1233. [Abstract]

Control or VAPA/B siRNA-transfected HEK293T cells are treated with DMSO or PI4KIIIbeta-IN-10 for 4 h. WB probed for TFEB and CTSB.

PI4KIIIbeta-IN-10 purchased from MedChemExpress. Usage Cited in: Autophagy. 2019 Jul;15(7):1214-1233. [Abstract]

Control or VAPA/B siRNA-transfected HEK293T cells are treated with DMSO or PI4KIIIbeta-IN-10 for 18 h and treated with bafilomycin A1 for 4 h. WBs probed with LC3.
Nat Chem Biol

Hippo pathway regulation by phosphatidylinositol transfer protein and phosphoinositides. [Abstract]

022 Oct;18(10):1076-1086. PMID: 35788180
EMBO J

Cholesterol transfer via endoplasmic reticulum contacts mediates lysosome damage repair. [Abstract]

2022 Dec 15;41(24):e112677. PMID: 36408828
Cell Rep

The Golgi-resident protein ACBD3 concentrates STING at ER-Golgi contact sites to drive export from the ER. [Abstract]

2022 Dec 20;41(12):111868. PMID: 36543137
J Cell Biol

Lipid exchange at ER-trans-Golgi contact sites governs polarized cargo sorting. [Abstract]

2024 Jan 1;223(1):e202307051. PMID: 37991810
J Cell Biol

Arf1-PI4KIIIβ positive vesicles regulate PI(3)P signaling to facilitate lysosomal tubule fission. [Abstract]

2023 Sep 4;222(9):e202205128. PMID: 37289133
Elife

CHIP as a membrane-shuttling proteostasis sensor. [Abstract]

2017 Nov 1;6:e29388. PMID: 29091030

PI4KIIIbeta-IN-10 purchased from MedChemExpress. Usage Cited in: Elife. 2017 Nov 1;6:e29388. [Abstract]

Inhibition of PI4KIIIβ by its specific inhibitor IN-10 for 20 min undocks EGFP-CHIP-K30A, but not farnesylated EGFP (EGFP-F) from cellular membranes.
mBio

Early enterovirus translation deficits extend viral RNA replication and elicit sustained MDA5-directed innate signaling. [Abstract]

2023 Dec 19;14(6):e0191523. PMID: 37962360
Sci Rep

Dynamic assessment of PI4P metabolism using split GFP based sensors. [Abstract]

2025 Aug 21;15(1):30805. PMID: 40841827
J Cell Sci

VAPB depletion alters neuritogenesis and phosphoinositide balance in motoneuron-like cells: relevance to VAPB-linked amyotrophic lateral sclerosis. [Abstract]

2019 Apr 3;132(7):jcs220061. PMID: 30745341
University of Miami

2026.
bioRxiv

2023 Mar 25.
Patent

US20220273624A1.

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 50 mg/mL (105.13 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.1027 mL

10.5135 mL

21.0270 mL

5 mM

0.4205 mL

2.1027 mL

4.2054 mL

10 mM

0.2103 mL

1.0513 mL

2.1027 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (5.26 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (5.26 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (5.26 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Protokoll

Kinase Assay^[1]

Lipid kinase assays are preformed using recombinant enzyme, phosphoinositides and γ³²P-ATP in a membrane capture assay. Each inhibitor (e.g., PI4KIIIbeta-IN-10) is diluted into 10% DMSO and kinase assay buffer. Upon completion of the reaction, 4 µL is spotted onto 0.2 µm nitrocellulose. The membrane is dried for 5 minutes under a heat lamp followed by 1×30 second wash and 6×5 min washes in 1M NaCl /1% Phosphoric Acid. The membrane is dried for 20 minutes under a heat lamp followed by overnight exposure to a phosphor screen and phosphorimaging followed on a Typhoon 9500. Intensities are quantified using SPOT. Specifications for each enzyme follow. L-α-Phosphatidylinositol and DOPS:DOPC lipids are sonicated in water to generate 1mg/mL PI:DOPS:DOPC. Reaction is set-up as follows 1) kinase assay buffer, PI:DOPS:DOPC, BSA and PI4KIIIβ, are combined in a total volume of 10 µL (2.5x solution); 2) 5 µL of inhibitor solution is added (5x solution) and incubated with enzyme mixture for 15 minutes; 3) 10 µL cold ATP and γ³²P-ATP are added (2.5x solution) to initiate the reaction which ran for 30 minutes. Final conditions are as follows: 20 mM Bis-Tris Propane pH 7.5, 10 mM MgCl₂, 0.075 mM Triton X-100, 0.5 mM EGTA, 1 mM DTT, 100 µM PI, 500 ng/µL BSA, 2.5 nM PI4KIIIβ, 2% DMSO, 10 µM ATP and 1 uCi γ³²P-ATP^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (278 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Rutaganira FU, et al. Design and Structural Characterization of Potent and Selective Inhibitors of Phosphatidylinositol 4 Kinase IIIβ. J Med Chem. 2016 Mar 10;59(5):1830-9. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.1027 mL	10.5135 mL	21.0270 mL	52.5674 mL
	5 mM	0.4205 mL	2.1027 mL	4.2054 mL	10.5135 mL
	10 mM	0.2103 mL	1.0513 mL	2.1027 mL	5.2567 mL
	15 mM	0.1402 mL	0.7009 mL	1.4018 mL	3.5045 mL
	20 mM	0.1051 mL	0.5257 mL	1.0513 mL	2.6284 mL
	25 mM	0.0841 mL	0.4205 mL	0.8411 mL	2.1027 mL
	30 mM	0.0701 mL	0.3504 mL	0.7009 mL	1.7522 mL
	40 mM	0.0526 mL	0.2628 mL	0.5257 mL	1.3142 mL
	50 mM	0.0421 mL	0.2103 mL	0.4205 mL	1.0513 mL
	60 mM	0.0350 mL	0.1752 mL	0.3504 mL	0.8761 mL
	80 mM	0.0263 mL	0.1314 mL	0.2628 mL	0.6571 mL
	100 mM	0.0210 mL	0.1051 mL	0.2103 mL	0.5257 mL

Keywords

PI4KIIIbeta-IN-10

15 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

PI4KIIIbeta-IN-10

Publications Citing Use of MedChemExpress (MCE) PI4KIIIbeta-IN-10

Alle PI4K Isoform-spezifische Produkte anzeigen

Alle PI3K Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (15)

Lösungsmittel & Löslichkeit

Protokoll

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

PI4KIIIbeta-IN-10 Related Classifications

HY-100198 Related Classifications